Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
Wyeth Takes Over Distribution of BeneFIX® in Europe
 

Wyeth announced that it has assumed all marketing and distribution rights in Europe to BeneFIX®, its recombinant factor IX product. Wyeth, a global pharmaceutical company with U.S. headquarters in Madison, NJ, manufactures BeneFIX®. The transfer of rights came on June 30, 2007, at the end of a 10-year distribution agreement between Baxter Healthcare Corporation and Genetics Institute, which originally developed BeneFIX®. The institute was acquired by Wyeth in 1996.

"We are pleased to broaden Wyeth’s range of therapeutic offerings for the hemophilia community in Europe," said Cavan Redmond, executive vice president and general manager, BioPharma Business Unit at Wyeth Pharmaceuticals. "We also have plans—pending European regulatory approval—to introduce new convenience enhancements to BeneFIX® later this year."

BeneFIX® is indicated for the control and prevention of bleeding episodes and bleeding related to surgery in patients with hemophilia B.

Source: Wyeth news release dated July 3, 2007